Functional diversity and regulation of IL-9-producing T cells in cancer immunotherapy
- 18 October 2024
- journal article
- review article
- Published by Elsevier in Cancer Letters
- Vol. 606, 217306
Abstract
No abstract availableKeywords
Funding Information
- Cancer Prevention and Research Institute of Texas (RR210067)
- National Cancer Institute (1R01CA248111-01A1, R01CA288403, R01CA258477-01, 1R37CA251318-01, R01CA278911)
This publication has 67 references indexed in Scilit:
- Human gamma-delta (γδ) T cell therapy for glioblastoma: A novel alternative to overcome challenges of adoptive immune cell therapyCancer Letters, 2023
- PDE4D/cAMP/IL-23 axis determines the immunotherapy efficacy of lung adenocarcinoma via activating the IL-9 autocrine loop of cytotoxic T lymphocytesCancer Letters, 2023
- Immune-checkpoint inhibitor resistance in cancer treatment: Current progress and future directionsCancer Letters, 2023
- CD8+ T cell exhaustion and cancer immunotherapyCancer Letters, 2022
- Immune checkpoint inhibitor resistance in hepatocellular carcinomaCancer Letters, 2022
- IL‐9 promotes the survival and function of human melanoma‐infiltrating CD4+CD8+ double‐positive T cellsEuropean Journal of Immunology, 2016
- Heterogeneity in the Differentiation and Function of CD8+ T CellsArchivum Immunologiae et Therapiae Experimentalis, 2014
- Murine Th9 cells promote the survival of myeloid dendritic cells in cancer immunotherapyCancer Immunology, Immunotherapy, 2014
- Recruitment and Phenotypic Characteristics of Interleukin 9-Producing CD4+ T Cells in Malignant Pleural EffusionLung, 2013
- Tc9 cells, a new subset of CD8+ T cells, support Th2‐mediated airway inflammationEuropean Journal of Immunology, 2012